Results 61 to 70 of about 18,936 (261)

Synthesis and clinical application of new drugs approved by FDA in 2022

Molecular Biomedicine, 2023
The pharmaceutical industry had a glorious year in 2022, with a total of 37 new drugs including 20 new chemical entities (NCEs) and 17 new biological entities (NBEs) approved by the Food and Drug Administration (FDA).
Jing-Yi Zhang, Ya-Tao Wang, Lu Sun, Sai-Qi Wang, Zhe-Sheng Chen   +4 more
doaj   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Food Effect and Formulation: How Soluble Fillers Affect the Disintegration and Dissolution of Tablets in Viscous Simulated Fed State Media

Pharmaceutics
The food-induced viscosity of the media can alter tablet disintegration and eventually the release of the drug it contains. The extent of this retardation depends on tablet formulation factors, such as the solubility of its excipients.
Muhammad Farooq Umer, Valentin Stahl, Jozef Al-Gousous, Thomas Nawroth, Wei-Jhe Sun, Fang Wu, Wenlei Jiang, Zongming Gao, Peter Langguth   +8 more
doaj   +1 more source

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

Orphan Drug Approval in Canada, 1999-2022: A Cross-sectional Study [PDF]

International Journal of Health Policy and Management
The number of drugs for orphan indications has been increasing significantly in Canada and the federal government recently announced an investment of $1.5 billion dollars over 3 years primarily directed at helping to fund the cost of these drugs.
Joel Lexchin
doaj   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source

Improving the Effectiveness of FDA Drug Inspection [PDF]

Operations Research, 1992
The evaluation and the allocation of inspection resources is a problem faced by private sector firms as well as by several government agencies. This paper reports the development and the use by the Food and Drug Administration (FDA) of decision making tools for measuring the performance of their drug inspection activities in which data are collected ...
Ronald K. Klimberg, Charles S. Revelle, Jared L. Cohon   +2 more
openaire   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

Molecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens, Anouk Mentink, Tom Niessink, Frank Coumans, Leonie Mekenkamp, Ruchi Bansal, Jeroen Hiltermann   +6 more
wiley   +1 more source

Erythrocyte PIG‐A mutant frequencies in cancer patients receiving cisplatin

Cancer Medicine
Background Cisplatin is a primary chemotherapy choice for various solid tumors. DNA damage caused by cisplatin results in apoptosis of tumor cells. Cisplatin‐induced DNA damage, however, may also result in mutations in normal cells and the initiation of ...
Vasily N. Dobrovolsky, Omar T. Atiq, Robert H. Heflich, Mackean Maisha, Page B. McKinzie, Mason G. Pearce, Timothy W. Robison   +6 more
doaj   +1 more source

Association of the FDA Amendment Act with trial registration, publication, and outcome reporting

Trials, 2017
Background Selective clinical trial publication and outcome reporting has the potential to bias the medical literature. The 2007 Food and Drug Administration (FDA) Amendment Act (FDAAA) mandated clinical trial registration and outcome reporting on ...
Adam T. Phillips, Nihar R. Desai, Harlan M. Krumholz, Constance X. Zou, Jennifer E. Miller, Joseph S. Ross   +5 more
doaj   +1 more source